🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

17,82 USD

Máx. histórico

178,74

2145 días

Split 1:6 del 12/07/2012

Caída desde máximo

-90,03%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+1,42%

Cierre anterior

17,57

Rango de hoy

17,52 – 18,77

Volumen hoy

2.596.193

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 19 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
27/12/2010 12,24 12,54 11,88 12,42 +0,98% 5,39% 210.967
23/12/2010 12,18 12,54 12,12 12,30 +0,49% 3,45% 136.217
22/12/2010 12,42 12,42 12,18 12,24 -1,45% 1,93% 253.517
21/12/2010 12,30 12,54 12,00 12,42 +1,47% 4,39% 154.133
20/12/2010 12,12 12,48 12,00 12,24 +0,99% 3,96% 170.000
17/12/2010 11,88 12,24 11,58 12,12 +2,02% 5,56% 376.017
16/12/2010 11,82 12,36 11,70 11,88 +1,02% 5,58% 177.833
15/12/2010 11,46 11,88 11,46 11,76 +2,08% 3,66% 162.350
14/12/2010 11,04 11,70 11,04 11,52 +4,92% 5,98% 303.350
13/12/2010 11,16 11,28 10,92 10,98 -1,08% 3,23% 137.567
10/12/2010 11,16 11,22 10,98 11,10 +0,00% 2,15% 145.733
09/12/2010 11,22 11,28 11,04 11,10 -1,07% 2,14% 153.900
08/12/2010 10,98 11,28 10,98 11,22 +1,63% 2,73% 146.500
07/12/2010 10,80 11,10 10,62 11,04 +2,22% 4,44% 209.867
06/12/2010 10,80 10,98 10,56 10,80 -0,55% 3,89% 150.033
03/12/2010 10,74 10,92 10,44 10,86 +0,00% 4,47% 158.767
02/12/2010 11,10 11,10 10,74 10,86 -1,63% 3,24% 128.733
01/12/2010 11,10 11,16 10,74 11,04 +0,00% 3,78% 108.617
30/11/2010 10,68 11,10 10,50 11,04 +1,66% 5,62% 202.383
29/11/2010 10,68 10,92 10,56 10,86 +1,69% 3,37% 135.750
26/11/2010 10,86 11,10 10,68 10,68 -2,20% 3,87% 40.967
24/11/2010 11,04 11,28 10,68 10,92 -0,55% 5,43% 186.067
23/11/2010 11,16 11,22 10,86 10,98 -2,66% 3,23% 181.017
22/11/2010 11,16 11,28 10,80 11,28 +1,08% 4,30% 134.700
19/11/2010 11,34 11,52 11,10 11,16 -1,59% 3,70% 367.917
18/11/2010 11,10 11,34 10,92 11,34 +3,28% 3,78% 236.267
17/11/2010 10,62 10,98 10,56 10,98 +3,98% 3,95% 125.483
16/11/2010 10,98 11,10 10,50 10,56 -4,86% 5,46% 234.200
15/11/2010 10,98 11,28 10,92 11,10 +1,09% 3,28% 155.583
12/11/2010 11,04 11,28 10,86 10,98 -2,14% 3,80% 115.750